Of note, these subtypes had been previously identified and functionally validated as playing important roles in tumor control in response to immunotherapy, driven by IFN-γ stimulation downstream of lymphocyte-myeloid cell crosstalk (21, 25). The gene discussed is IFNG; the disease is neoplasm.